Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps

References

• LozanoR, NaghaviM, ForemanK, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–2128. doi:10.1016/S0140-6736(12)61728-023245604
   PubMed Web of Science ®Google Scholar
• World Health Organization (WHO) COPD key facts; 2018. Available from: http://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 416, 2020..
   Google Scholar
• FordES, MurphyLB, KhavjouO, GilesWH, HoltJB, CroftJB. Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest. 2015;147(1):31–45. doi:10.1378/chest.14-097225058738
   PubMed Web of Science ®Google Scholar
• Global Strategy for Diagnosis, Management and Prevention of COPD. The Global Initiative for Chronic Obstructive Lung Diseases (GOLD). 2020 report. Available from: https://goldcopd.org/gold-reports/. Accessed 416, 2020.
   Google Scholar
• CookNS, KostikasJ, GruenbergerJ-B, et al. Patients’ perspectives on COPD: findings from a social media listening study. ERJ Open Res. 2019;5(1):00128–2018. doi:10.1183/23120541.00128-2018
   PubMedGoogle Scholar
• MackayAJ, KostikasK, MurrayL, et al. Patient-reported outcomes for the detection, quantification, and evaluation of chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2018;198(6):730–738. doi:10.1164/rccm.201712-2482CI29671615
   PubMed Web of Science ®Google Scholar
• AgustíAG, NogueraA, SauledaJ, SalaE, PonsJ, BusquetsX. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003;21(2):347–360. doi:10.1183/09031936.03.0040570312608452
   PubMed Web of Science ®Google Scholar
• GarrowAP, YorkeJ, KhanN, VestboJ, SinghD, TysonS. Systematic literature review of patient-reported outcome measures used in assessment and measurement of sleep disorders in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:293–307. doi:10.2147/COPD.S6809325709424
   PubMed Web of Science ®Google Scholar
• SpruitMA, VercoulenJH, SprangersMAG, WoutersEFM. FAntasTIGUE consortium. Fatigue in COPD: an important yet ignored symptom. Lancet Respir Med. 2017;5(7):542–544. doi:10.1016/S2213-2600(17)30158-328438501
   PubMed Web of Science ®Google Scholar
• Janaudis-FerreiraT, BeauchampMK, RoblesPG, GoldsteinRS, BrooksD. Measurement of activities of daily living in patients with COPD: a systematic review. Chest. 2014;145(2):253–271. doi:10.1378/chest.13-001623681416
   PubMed Web of Science ®Google Scholar
• BurgeAT, LeeAL, KeinC, et al. Prevalence and impact of urinary incontinence in men with chronic obstructive pulmonary disease: a questionnaire survey. Physiotherapy. 2017;103(1):53–58. doi:10.1016/j.physio.2015.11.00427036613
   PubMed Web of Science ®Google Scholar
• ChenS, SmallM, LindnerL, XuX. Symptomatic burden of COPD for patients receiving dual or triple therapy. Int J Chron Obstruct Pulmon Dis. 2018;13:1365–1376. doi:10.2147/COPD.S16371729731624
   PubMed Web of Science ®Google Scholar
• SanduzziA, BalboP, CandoliP, et al. COPD: adherence to therapy. Multidiscip Respir Med. 2014;9(1):60. doi:10.1186/2049-6958-9-6025485108
   PubMedGoogle Scholar
• SinDD, StafinskiT, NgYC, BellNR, JacobsP. The impact of chronic obstructive pulmonary disease on work loss in the United States. Am J Respir Crit Care Med. 2002;165(5):704–707. doi:10.1164/ajrccm.165.5.210405511874818
   PubMed Web of Science ®Google Scholar
• JonesPW, BrusselleG, Dal NegroRW, et al. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105(1):57–66. doi:10.1016/j.rmed.2010.09.00420932736
   PubMed Web of Science ®Google Scholar
• BuistAS, McBurnieMA, VollmerWM, et al. International variation in the prevalence of COPD (the BOLD study): a population-based prevalence study. Lancet. 2007;370(9589):741–750. doi:10.1016/S0140-6736(07)61377-417765523
   PubMed Web of Science ®Google Scholar
• GarridoPC, de Miguel DíezJ, GutiérrezJR, et al. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study. Health Qual Life Outcomes. 2006;4:31. doi:10.1186/1477-7525-4-3116719899
   PubMed Web of Science ®Google Scholar
• BrienSB, LewithGT, ThomasM. Patient coping strategies in COPD across disease severity and quality of life: a qualitative study. NPJ Prim Care Respir Med. 2016;26:16051. doi:10.1038/npjpcrm.2016.5127629237
   PubMed Web of Science ®Google Scholar
• NgTP, NitiM, TanWC, CaoZ, OngKC, EngP. Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med. 2007;167(1):60–67. doi:10.1001/archinte.167.1.6017210879
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims; 2009 Available from: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf. Accessed 4 21, 2020.
   Google Scholar
• EkströmM, SundhJ, LarssonK. Patient reported outcome measures in chronic obstructive pulmonary disease: which to use? Expert Rev Respir Med. 2016;10(3):351–362. doi:10.1586/17476348.2016.114659526808786
   PubMed Web of Science ®Google Scholar
• CazzolaM, HananiaNA, MacNeeW, RüdellK, HackfordC, TamimiN. A review of the most common patient-reported outcomes in COPD–revisiting current knowledge and estimating future challenges. Int J Chron Obstruct Pulmon Dis. 2015;10:725–738. doi:10.2147/COPD.S7736825897216
   PubMed Web of Science ®Google Scholar
• SuissaS. Lung function decline in COPD trials: bias from regression to the mean. Eur Respir J. 2008;32(4):829–831. doi:10.1183/09031936.0010300818827150
   PubMed Web of Science ®Google Scholar
• ZuWallackRL, NiciL. Modifying the course of chronic obstructive pulmonary disease: looking beyond the FEV1. COPD. 2012;9(6):637–648. doi:10.3109/15412555.2012.71066822958136
   PubMedGoogle Scholar
• KostikasK, GreulichT, MackayAJ, et al. Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study. ERJ Open Res. 2019;5(1):00243–2018. doi:10.1183/23120541.00243-201830815470
   PubMedGoogle Scholar
• JonesPW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56(11):880–887. doi:10.1136/thorax.56.11.88011641515
   PubMed Web of Science ®Google Scholar
• JonesP, MiravitllesM, van der MolenT, KulichK. Beyond FEV1 in COPD: a review of patient-reported outcomes and their measurement. Int J Chron Obstruct Pulmon Dis. 2012;7:697–709. doi:10.2147/COPD.S3267523093901
   PubMed Web of Science ®Google Scholar
• DonohueJF, JonesPW, BartelsC, et al. Correlations between FEV1 and patient-reported outcomes: a pooled analysis of 23 clinical trials in patients with chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2018;49:11–19. doi:10.1016/j.pupt.2017.12.00529277690
   PubMed Web of Science ®Google Scholar
• CazzolaM, MacNeeW, MartinezFJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008;31(2):416–469. doi:10.1183/09031936.0009930618238951
   PubMed Web of Science ®Google Scholar
• LeidyNK, WilcoxTK, JonesPW, et al. Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT): a patient-reported outcome (PRO) measure. Value Health. 2010;13(8):965–975. doi:10.1111/j.1524-4733.2010.00772.x20659270
   PubMed Web of Science ®Google Scholar
• HowardK, BerryP, PetrilloJ, et al. Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). Value Health. 2012;15(8):1042–1050. doi:10.1016/j.jval.2012.06.01823244806
   PubMed Web of Science ®Google Scholar
• EakinEG, ResnikoffPM, PrewittLM, RiesAL, KaplanRM. Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. Chest. 1998;113(3):619–624. doi:10.1378/chest.113.3.6199515834
   PubMed Web of Science ®Google Scholar
• SchünemannHJ, GriffithL, JaeschkeR, et al. A comparison of the original chronic respiratory questionnaire with a standardized version. Chest. 2003;124(4):1421–1429. doi:10.1378/chest.124.4.142114555575
   PubMed Web of Science ®Google Scholar
• PartridgeMR, MiravitllesM, StåhlE, KarlssonN, SvenssonK, WelteT. Development and validation of the capacity of daily living during the morning questionnaire and the global chest symptoms questionnaire in COPD. Eur Respir J. 2010;36(1):96–104. doi:10.1183/09031936.0012370919897551
   PubMed Web of Science ®Google Scholar
• MocarskiM, ZaiserE, TrundellD, MakeBJ, HareendranA. Evaluation of the psychometric properties of the Nighttime symptoms of COPD instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475–487. doi:10.2147/COPD.S7577625834415
   PubMed Web of Science ®Google Scholar
• Garcia GilE, ZaiserE, HareendranA, MakeBJ. A summary of the development and validation of the Early Morning Symptoms of COPD Instrument (EMSCI). Am J Respir Crit Care Med. 2017;195:A3661. doi:10.1164/rccm.201701-0150WS
   Web of Science ®Google Scholar
• MahlerDA, BrunelV, WhiteT, et al. Development and validation of an innovative self-administered computerized (SAC) version of baseline/transition dyspnea index (BDI/TDI) for evaluating breathlessness in patients with COPD: the BLAZE study. Eur Respir J. 2013;42(Suppl 57):P718.
   Google Scholar
• HsuJY, StoneRA, Logan-SinclairRB, WorsdellM, BusstCM, ChungKF. Coughing frequency in patients with persistent cough: assessment using a 24 hour ambulatory recorder. Eur Respir J. 1994;7(7):1246–1253. doi:10.1183/09031936.94.070712467925902
   PubMed Web of Science ®Google Scholar
• BorgGA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc. 1982;14(5):377–381. doi:10.1249/00005768-198205000-000127154893
   PubMed Web of Science ®Google Scholar
• JonesPW, RennardSI, AgustiA, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12(1):55. doi:10.1186/1465-9921-12-5521518460
   PubMed Web of Science ®Google Scholar
• JonesPW, QuirkFH, BaveystockCM. The St George’s respiratory questionnaire. Respir Med. 1991;85(SupplB):25–31. doi:10.1016/S0954-6111(06)80166-61759018
   PubMed Web of Science ®Google Scholar
• MeguroM, BarleyEA, SpencerS, JonesPW. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest. 2007;132(2):456–463. doi:10.1378/chest.06-070217646240
   PubMed Web of Science ®Google Scholar
• JonesPW, HardingG, BerryP, WiklundI, ChenWH, Kline LeidyN. Development and first validation of the COPD assessment test. Eur Respir J. 2009;34(3):648–654. doi:10.1183/09031936.0010250919720809
   PubMed Web of Science ®Google Scholar
• BirringSS, PrudonB, CarrAJ, SinghSJ, MorganMD, PavordID. Development of a symptom specific health status measure for patients with chronic cough: leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339–343. doi:10.1136/thorax.58.4.33912668799
   PubMed Web of Science ®Google Scholar
• CrawfordB, MonzB, HohlfeldJ, et al. Development and validation of a cough and sputum assessment questionnaire. Respir Med. 2008;102(11):1545–1555. doi:10.1016/j.rmed.2008.06.00918662868
   PubMed Web of Science ®Google Scholar
• AcquadroC, BerzonR, DuboisD, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6(5):522–531. doi:10.1046/j.1524-4733.2003.65309.x14627058
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products. European Medicines Agency; 2005 Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-guidance-use-healthrelated-quality-life-hrql-measures-evaluation_en.pdf. Accessed 421, 2020.
   Google Scholar
• JonesP, LareauS, MahlerDA. Measuring the effects of COPD on the patient. Respir Med. 2005;99(Suppl):B:S11–S18. doi:10.1016/j.rmed.2005.09.011
   Web of Science ®Google Scholar
• U.S. Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research. Chronic Obstructive Pulmonary Disease: use of the St. George’s Respiratory Questionnaire as a PRO assessment tool guidance for industry; 2018 Available from: https://www.fda.gov/downloads/drugs/guidances/ucm071575.pdf. Accessed April 21, 2020.
   Google Scholar
• EngströmCP, PerssonLO, LarssonS, SullivanM. Health-related quality of life in COPD: why both disease-specific and generic measures should be used. Eur Respir J. 2001;18(1):69–76. doi:10.1183/09031936.01.0004490111510808
   PubMed Web of Science ®Google Scholar
• RolstadS, AdlerJ, RydénA. Response burden and questionnaire length: is shorter better? A review and meta-analysis. Value Health. 2011;14(8):1101–1108. doi:10.1016/j.jval.2011.06.00322152180
   PubMed Web of Science ®Google Scholar
• BodartS, ByromB, CrescioniM, EremencoS, FloodE. Perceived burden of completion of patient-reported outcome measures in clinical trials: results of a preliminary study. Ther Innov Regul Sci. 2019;53(3):318–323. doi:10.1177/216847901878805330058368
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services Food and Drug Administration. Clinical Outcome Assessment (COA) Qualification Program. Available from: https://www.fda.gov/drugs/drug-development-tool-ddt-qualification-programs/clinical-outcome-assessment-coa-qualification-program. Accessed 423, 2020..
   Google Scholar